Journals / Turkish Journal of Gastroenterology / 2012 / Cilt: 23 - Sayı: 4

Gastirik ülsere karşı kefirin koruyucu aktivitesi üzerine bir araştırma

A study on the protective activity of kefir against gastric ulcer

Pages
333–338
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This requires further evaluation in larger series.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: The effect of kefir on peptic ulcer disease was evaluated in an experimental model, with non-steroid anti-inflammatory drugs, together with the determination of gastric mucus secretion by quantitative digital histochemistry.
📊
Key Findings & Data:Materials and Methods: The experimental group included 28 male albino Wistar rats.
💡
Conclusion & Impact:This requires further evaluation in larger series.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: The effect of kefir on peptic ulcer disease was evaluated in an experimental model, with non-steroid anti-inflammatory drugs, together with the determination of gastric mucus secretion by quantitative digital histochemistry. Materials and Methods: The experimental group included 28 male albino Wistar rats. After a diet with standard rat bait for 7 days, 14 rats were fed with kefir for 7 days while the others were kept on the same diet. At the 14th day, indomethacin was injected to 7 of the rats fed on kefir and to 7 of the rats on standard rat bait. All the rats were sacrificed after 4 hours. Gastric erosion and ulceration were scored histopathologically. Mucosal mucus was quantified by image analysis, and periodic acid-Schiff stained area percentage was determined. Results: Erosion and ulceration were identified only in cases that received indomethacin. In the cases on kefir, erosion was identified in 6 cases (86%) and ulceration in 1 case. Rats fed on standard diet had erosion in 4 cases (57%) and ulceration in 3 (43%), but the difference was statistically insignificant (Mann-Whitney test, p=0.25). The stained area percentage for gastric mucus was not different between the four groups (Kruskal-Wallis test, p=0.313). Conclusions: These findings suggest that kefir does not change gastric mucus secretion. Although statistically insignificant, as there were more cases with ulceration in cases on the rat diet, kefir might have a beneficial effect on peptic ulcer disease induced by non-steroid anti-inflammatory drug. This requires further evaluation in larger series.

Özet

Amaç: Kefirin nonsteroid anti-inflamatuvar ilaç ile peptik ülser hastalığı üzerine, kefirin mide mukus bariyerinin miktarı ve etkinliği üzerindeki etkisi deneysel bir modelle araştırılmıştır. Gereç ve Yöntem: 28 Wistar türü erkek sıçan üzerinde yapılan araştırmada 14 denek kontrol olarak 15 gün boyunca standart olarak grup başına 300 gram standart sıçan yemi ile beslenmiş, diğer 14 denek ise 7 gün yem alıp bu günden sonra 300 gram yem ile 450 gram kefir karıştırılarak beslenmiştir. Her iki gruptan 7 deneğe subkutan 30 mg/kg indometazin verilip 4 saat sonra sakrifiye edilmiştir. Histopatolojik inceleme ile gastrik ülserasyon gelişimi skorlanmış ve imaj analizi ile mukus miktarı kesitlerde saptanmıştır. Bulgular: Ülserasyon skorları karşılaştırıldığında kefir alan ve almayan gruplar arasında fark yoktur. Mikroskopik incelemede sadece indometazin verilen gruplarda gastrik ülserasyon ve erozyon saptanmıştır. Kefir almayan kontrol grubunda 4 (%57) olguda erozyon ve 3 (%43) olguda ülserasyon saptanmıştır. Kefir alan grupta erozyon 6 olguda (%86), ülserasyon 1 (%14) olguda saptanmıştır. Gruplar arasında istatistiksel fark saptanmamıştır (Mann Whitney Test p=0.25 ). Kontrol grubunu oluşturan deneklerde kefir alımı olmaksızın, gastrik mukozada mukus salgısının bulunduğu alan yüzdesi % 6.04±2.94 olarak bulunmuştur. Kefir alanlarda ise %5.90±3.15dir. Kefir almayan ve indometazin alanlarda bu oran %4.65±1.55 olup, kefir alan ve indometazin alanlarda ise %3.75±2.5 bulunmuştur. Bu da istatistiksel analiz gruplar arasında fark bulunmadığını ortaya koymuştur (Kruskal Wallis p= 0.313, r=0.52). Sonuç: Bu bulgular kefirin gastrik mukus miktarını ya da koruyuculuğu arttırdığını desteklememektedir. İstatistiksel sonuçlar önemsiz çıksa da, nonsteroid anti-inflamatuvar ilaç ile ülser yapılan ve kefir ile beslenen grupta sonuçların daha iyi çıkması bu çalışmanın daha kapsamlı olarak yeniden yapılması düşünülebilir.

🔖

Cite This Article

ORHAN, Y. T., KARAGÖZLÜ, C., SARIOĞLU, S., YILMAZ, O., MURAT, N., GİDENER, S. (2012). Gastirik ülsere karşı kefirin koruyucu aktivitesi üzerine bir araştırma. Turkish Journal of Gastroenterology, Cilt: 23 - Sayı: 4, 333–338. https://ajindex.com/articles/409706

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Evensthtein ZM. Use of kefir for stimulation of gastric secretion and acid fermentation in patients with pulmonary tuberculosis. Prob Tuber 1978; 2: 82-4
  2. Otles S, Cagindi O. Kefir: a probiotic dairy composition, nutritional and therapeutic aspects. Pakistan J Nutr 2003; 829: 54-9
  3. Saloff–Coste CS. Kefir. Danone Vitapole 2002, Available from URL: http://www.danonevitapole.com/nutri_views/newsletter/eng/news_11/conclu.html (1 sur 2)
  4. Alp M, Count S, Grant AV. Personality pattern and emotional stress in genesis at gastric ulcer. Gas 1970; 11: 773-7
  5. Zhang X, Tajima K, Kageyema K, Kyoi T. Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats. World J Gastroenterol 2008; 14: 4784-90
  6. Morsy MA, Fouad AA. Mechanisms of gastroprotective effect of eugenol in indomethacin-induced ulcer in rats. Phytother Res 2008; 22: 1361-6
  7. Karagözlü C. Kefir: probiotic fermented milk product. 50th Anniversary of the University of Food Technology HIFFI 15-17 Oct. 2003 Plovdiv Bulgaria. Collection of Scientific Works of the HIFFI Plovdiv Vol: (L) 2003, 50: 2, 404-9, ISSN 0477-0250 UFTA Academic Publishing House, Plovdiv – Bulgaria
  8. Anonymous. Yoghurt Standard. TSE 1330. Ankara – TURKEY, 1990
  9. Anonymous. The OXOID Manual. Hampshire. 7th Edition. United Kingdom, 1995
  10. Thomson SW, Hunt RD. Selected histochemical methods. Illinois, USA: Charles C. Thomas Publisher, 1966; 40-1, 480-1, 762, 763
  11. Sarıoğlu S, Çelik A, Sakar M, et al. Methenamine silver staining quantitative digital histochemistry in chronic allograft nephropathy. Transplant Proc 2004; 36: 2991-2
  12. Kavukçu S, Soylu A, Türkmen M, et al. Unilateral ureteroperitoneostomy in the management of hypoproteinemia in nephrotic rats with normal renal function. Tohoku J Exp Med 2003; 2: 67-73
  13. Sis B, Sarıoğlu S, Somken S, et al. Desmoplasia quantified by computer-assisted image analysis: an independent prognostic marker in colorectal carcinoma. J Clin Pathol 2005; 58: 32-8
  14. SAS Institute. JMP user’s guide. Version 3.1. Cary, NC: SAS Institute Inc, 1999
  15. Chan FK, Leung WK. Peptic-ulcer disease. Lancet 2002; 21: 933-41
  16. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-5
  17. Marshall WME, Cole WM. Methods for making kefir and fermented milks based on kefir. J Dairy Res1985; 52: 44552
  18. Koroleva NS. Kefir and kumy starters. IDF Bul